Skip to content

Study · Animal study (in vivo) · sprague-dawley rats · 2021

12 results

Safety evaluation after acute and sub-chronic oral administration of high purity nicotinamide mononucleotide (NMN-C®) in Sprague-Dawley rats.

Cros C, Cannelle H, Laganier L, Grozio A, Canault M

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association12 Feb 2021Cited by 17 (Europe PMC)

PMID33587977 (opens in a new tab)DOI10.1016/j.fct.2021.112060 (opens in a new tab)PepBankPUB-33587977
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In rats, oral NMN-C did not cause mortality at the acute limit dose.

    In plain wordsIn rats, oral NMN-C did not cause deaths at the acute limit dose.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeAcute mortality
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Mortality · Whole body
    Studied dose
    2666 mg/kg · oralAs given in this study (Sprague-Dawley rats).

    Measurements

    Acute limit dose
    2666 mg/kg
    oral NMN-C

    Source sentences

    Summary
    Acute toxicity assay revealed that at an oral limit dose of 2666 mg/kg, NMN-C® did not lead to any mortality or treatment-related adverse signs.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, oral NMN-C did not cause treatment-related adverse signs at the acute limit dose.

    In plain wordsIn rats, oral NMN-C did not cause treatment-related adverse signs at the acute limit dose.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeAcute adverse signs
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    2666 mg/kg · oralAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    Acute toxicity assay revealed that at an oral limit dose of 2666 mg/kg, NMN-C® did not lead to any mortality or treatment-related adverse signs.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no toxic effects on body weight change.

    In plain wordsIn rats, repeated NMN-C administration showed no toxic effects on body weight change.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeBody weight change
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
    1 context sentence
    Summary · context
    Over a 90-day sub-chronic period of repeated oral administration of NMN-C® at doses of 375, 750 and 1500 mg/kg/d followed by a 28-day treatment-free recovery period,
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no toxic effects on food consumption.

    In plain wordsIn rats, repeated NMN-C administration showed no toxic effects on food consumption.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeFood consumption
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no toxic effects on water consumption.

    In plain wordsIn rats, repeated NMN-C administration showed no toxic effects on water consumption.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeWater consumption
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no toxic effects on feed conversion efficiency.

    In plain wordsIn rats, repeated NMN-C administration showed no toxic effects on feed conversion efficiency.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeFeed conversion efficiency
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no toxic effects in biochemical parameters.

    In plain wordsIn rats, repeated NMN-C administration showed no toxic effects in biochemical parameters.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeBiochemical parameters
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no toxic effects in blood parameters.

    In plain wordsIn rats, repeated NMN-C administration showed no toxic effects in blood parameters.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeBlood parameters
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no organ toxicity.

    In plain wordsIn rats, repeated NMN-C administration showed no organ toxicity.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeOrgan toxicity
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In rats, repeated NMN-C administration showed no toxic effects in histological examinations of major organs.

    In plain wordsIn rats, repeated NMN-C administration showed no toxic effects in major organ tissue examinations.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeOrgan histology
    Study

    Sprague-Dawley ratsn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    375, 750 and 1500 mg/kg/d · oral · 90 daysAs given in this study (Sprague-Dawley rats).

    Source sentences

    Summary
    NMN-C® appeared to be safe and did not promote toxic effects as seen from body weight change, food and water consumption, feed conversion efficiency, biochemical and blood parameters as well as organ toxicity and histological examinations of main organs.
  11. 11LabOther designSafety outcome

    In the tested experimental systems, NMN-C did not show mutagenicity.

    In plain wordsIn lab tests, NMN-C did not show mutagenicity.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeMutagenicity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the experimental conditions tested, NMN-C® was not mutagenic or genotoxic.
  12. 12LabOther designSafety outcome

    In the tested experimental systems, NMN-C did not show genotoxicity.

    In plain wordsIn lab tests, NMN-C did not show genotoxicity.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeGenotoxicity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the experimental conditions tested, NMN-C® was not mutagenic or genotoxic.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT06991712

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

Christopher Kai Shun Leungn = 13819 May 2025 to est. 31 Dec 2026

Glaucoma

Trial pageClinicalTrials.govUpdated 26 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.